ES2230109T5 - Procedimiento de analisis de la predisposicion genetica de un paciente a por lo menos una enfermedad y amplificacion adaptada a un procedimiento de este tipo. - Google Patents
Procedimiento de analisis de la predisposicion genetica de un paciente a por lo menos una enfermedad y amplificacion adaptada a un procedimiento de este tipo. Download PDFInfo
- Publication number
- ES2230109T5 ES2230109T5 ES00929650T ES00929650T ES2230109T5 ES 2230109 T5 ES2230109 T5 ES 2230109T5 ES 00929650 T ES00929650 T ES 00929650T ES 00929650 T ES00929650 T ES 00929650T ES 2230109 T5 ES2230109 T5 ES 2230109T5
- Authority
- ES
- Spain
- Prior art keywords
- drb1
- seq
- baselineskip
- alleles
- probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000003321 amplification Effects 0.000 title claims abstract description 61
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 60
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 title claims abstract description 33
- 201000010099 disease Diseases 0.000 title claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims description 61
- 238000004458 analytical method Methods 0.000 title description 42
- 108700028369 Alleles Proteins 0.000 claims abstract description 150
- 239000000523 sample Substances 0.000 claims abstract description 141
- 108091093088 Amplicon Proteins 0.000 claims abstract description 14
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 claims description 170
- 102100038823 RNA-binding protein 45 Human genes 0.000 claims description 166
- 206010036030 Polyarthritis Diseases 0.000 claims description 50
- 206010003246 arthritis Diseases 0.000 claims description 50
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 50
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 20
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 20
- 102000006390 HLA-B Antigens Human genes 0.000 claims description 18
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 18
- 238000009396 hybridization Methods 0.000 claims description 16
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 11
- 102000012153 HLA-B27 Antigen Human genes 0.000 claims description 10
- 108010061486 HLA-B27 Antigen Proteins 0.000 claims description 10
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims description 7
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 229930010555 Inosine Natural products 0.000 claims description 5
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 229960003786 inosine Drugs 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000005755 formation reaction Methods 0.000 claims description 4
- 101150000578 HLA-B gene Proteins 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 101000775252 Arabidopsis thaliana NADPH-dependent oxidoreductase 2-alkenal reductase Proteins 0.000 claims 1
- 101001041031 Homo sapiens Lariat debranching enzyme Proteins 0.000 claims 1
- 102100021155 Lariat debranching enzyme Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 102000039446 nucleic acids Human genes 0.000 abstract description 3
- 108020004707 nucleic acids Proteins 0.000 abstract description 3
- 150000007523 nucleic acids Chemical class 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 30
- 102000053602 DNA Human genes 0.000 description 30
- 241000282414 Homo sapiens Species 0.000 description 29
- 238000005457 optimization Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 238000000605 extraction Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007156 Spondylarthritis Diseases 0.000 description 2
- 201000002661 Spondylitis Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000237955 Nassarius Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- AKYUBKXEYODRLW-UHFFFAOYSA-N [N+](=O)([O-])C1OCCOC1.[Br] Chemical compound [N+](=O)([O-])C1OCCOC1.[Br] AKYUBKXEYODRLW-UHFFFAOYSA-N 0.000 description 1
- 208000037855 acute anterior uveitis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 1
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9906599A FR2793808B1 (fr) | 1999-05-20 | 1999-05-20 | Procede d'analyse de la predisposition genetique d'un patient a au moins une maladie |
| FR9906599 | 1999-05-20 | ||
| FR9915314A FR2793809B1 (fr) | 1999-05-20 | 1999-12-06 | Procede d'analyse de la predisposition genetique d'un patient a au moins une maladie et amplification adaptee a un tel procede |
| FR9915314 | 1999-12-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2230109T3 ES2230109T3 (es) | 2005-05-01 |
| ES2230109T5 true ES2230109T5 (es) | 2009-06-05 |
Family
ID=26234969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00929650T Expired - Lifetime ES2230109T5 (es) | 1999-05-20 | 2000-05-19 | Procedimiento de analisis de la predisposicion genetica de un paciente a por lo menos una enfermedad y amplificacion adaptada a un procedimiento de este tipo. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7060438B1 (enExample) |
| EP (1) | EP1179091B2 (enExample) |
| JP (1) | JP2003500067A (enExample) |
| CN (1) | CN1351672A (enExample) |
| AT (1) | ATE279535T1 (enExample) |
| AU (1) | AU772175B2 (enExample) |
| BR (1) | BR0010739A (enExample) |
| CA (1) | CA2374440A1 (enExample) |
| DE (1) | DE60014887T3 (enExample) |
| ES (1) | ES2230109T5 (enExample) |
| FR (1) | FR2793809B1 (enExample) |
| WO (1) | WO2000071750A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2829580B1 (fr) | 2001-09-07 | 2004-02-13 | Bio Merieux | Procede de lecture, de detection ou de quantification, hybrides ou complexes utilises dans ce procede et biopuce mettant en oeuvre ledit procede |
| WO2004047007A1 (en) | 2002-11-15 | 2004-06-03 | Bioarray Solutions, Ltd. | Analysis, secure access to, and transmission of array images |
| EP1536021A1 (en) * | 2003-11-27 | 2005-06-01 | Consortium National de Recherche en Genomique (CNRG) | Method for HLA typing |
| US7848889B2 (en) * | 2004-08-02 | 2010-12-07 | Bioarray Solutions, Ltd. | Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification |
| FR2881437B1 (fr) | 2005-01-31 | 2010-11-19 | Biomerieux Sa | Procede pour le diagnostic/pronostic d'un syndrome septique |
| FR2906537A1 (fr) | 2006-09-28 | 2008-04-04 | Biomerieux Sa | Procede de diagnostic in vitro du cancer broncho-pulmonaire par detection des transcrits majoritaires alternatifs du gene klk8 codant la kallicreine 8 et son utilisation pour le pronostic de survie |
| US20130096024A1 (en) * | 2010-04-27 | 2013-04-18 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Method for detecting the susceptibility to develop adverse side effects related to bioimplants |
| EP2576815B1 (en) | 2010-06-04 | 2018-02-14 | Biomérieux | Method for the prognosis of colorectal cancer |
| US9110079B2 (en) | 2010-09-29 | 2015-08-18 | Biomerieux | Method and kit for establishing an in vitro prognosis on a patient exhibiting SIRS |
| WO2012129758A1 (en) | 2011-03-25 | 2012-10-04 | Biomerieux | Method and kit for determining in vitro probability for individual to suffer from colorectal cancer |
| EP3000897B1 (en) | 2013-05-21 | 2019-10-16 | Biomérieux | Colorectal cancer prognosis agent kit |
| EP3620984B1 (en) | 2018-09-06 | 2024-04-10 | Accenture Global Solutions Limited | Digital quality control using computer visioning with deep learning |
| WO2025172242A1 (en) | 2024-02-13 | 2025-08-21 | bioMérieux | Method of assessing the risk of death of a patient |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567809A (en) * | 1986-03-13 | 1996-10-22 | Hoffmann-La Roche Inc. | Methods and reagents for HLA DRbeta DNA typing |
| US5468611A (en) * | 1990-06-27 | 1995-11-21 | The Blood Center Research Foundation, Inc. | Method for HLA typing |
| NL9002259A (nl) * | 1990-10-17 | 1992-05-18 | Eurodiagnostics B V | Werkwijze voor het bepalen van een genotype door het vergelijken van de nucleotidensequentie van leden van een genfamilie, alsmede kit voor het opsporen van genetische variaties. |
| GB9024005D0 (en) | 1990-11-05 | 1990-12-19 | British Bio Technology | Process for amplifying nucleic acid |
| FR2679252B1 (fr) * | 1991-07-17 | 1993-12-10 | Bio Merieux | Systeme de sondes permettant d'effectuer le typage hla dr, et procede de typage utilisant lesdites sondes. |
| US5976789A (en) * | 1991-07-17 | 1999-11-02 | Bio Merieux | System of probes enabling HLA-DR typing to be performed, and typing method using said probes |
| JPH0690757A (ja) * | 1991-08-23 | 1994-04-05 | Kitasato Inst:The | Ｈｌａ−ｄｒタイピング用塩基配列群とそれを用いた ｈｌａ−ｄｒタイピング法 |
| JPH08308596A (ja) * | 1995-03-10 | 1996-11-26 | Wakunaga Pharmaceut Co Ltd | Ｈｌａの検出 |
| US5939542A (en) | 1995-03-10 | 1999-08-17 | Wakunaga Seiyaku Kabushiki Kaisha | Detection of HLA-DR |
| WO1997020070A1 (en) * | 1995-11-29 | 1997-06-05 | The Anthony Nolan Bone Marrow Trust | Methods for separating and/or identifying dna molecules |
| FR2749308B1 (fr) * | 1996-06-03 | 1998-07-24 | Bio Merieux | Sondes nucleotidiques et procede pour determiner le typage hla dqb1 |
| AU6321998A (en) * | 1997-02-11 | 1998-08-26 | William H. Hildebrand | Class i sequence based typing of hla-a, -b, and -c alleles by direct dna sequencing |
| EP0887423A1 (en) * | 1997-06-26 | 1998-12-30 | Biotest Ag | A method for determining the Histocompatibility locus antigen class II |
| JP2001512694A (ja) * | 1997-08-11 | 2001-08-28 | ビジブル・ジェネティクス・インコーポレーテッド | Ｄｎａのｈｌａクラスｉタイプを決定するための方法およびキット |
| US5910413A (en) * | 1997-10-10 | 1999-06-08 | Visible Genetics, Inc. | Method and kit for amplification, sequencing and typing of classical HLA class I genes |
-
1999
- 1999-12-06 FR FR9915314A patent/FR2793809B1/fr not_active Expired - Fee Related
-
2000
- 2000-05-19 AU AU47660/00A patent/AU772175B2/en not_active Ceased
- 2000-05-19 WO PCT/FR2000/001385 patent/WO2000071750A1/fr not_active Ceased
- 2000-05-19 DE DE60014887T patent/DE60014887T3/de not_active Expired - Lifetime
- 2000-05-19 EP EP00929650A patent/EP1179091B2/fr not_active Expired - Lifetime
- 2000-05-19 CA CA002374440A patent/CA2374440A1/fr not_active Abandoned
- 2000-05-19 US US09/979,088 patent/US7060438B1/en not_active Expired - Fee Related
- 2000-05-19 ES ES00929650T patent/ES2230109T5/es not_active Expired - Lifetime
- 2000-05-19 AT AT00929650T patent/ATE279535T1/de not_active IP Right Cessation
- 2000-05-19 JP JP2000620127A patent/JP2003500067A/ja not_active Ceased
- 2000-05-19 BR BR0010739-5A patent/BR0010739A/pt not_active Application Discontinuation
- 2000-05-19 CN CN00807807A patent/CN1351672A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1179091A1 (fr) | 2002-02-13 |
| DE60014887T3 (de) | 2009-09-24 |
| AU772175B2 (en) | 2004-04-08 |
| ATE279535T1 (de) | 2004-10-15 |
| EP1179091B2 (fr) | 2009-02-25 |
| ES2230109T3 (es) | 2005-05-01 |
| EP1179091B1 (fr) | 2004-10-13 |
| BR0010739A (pt) | 2002-02-19 |
| AU4766000A (en) | 2000-12-12 |
| JP2003500067A (ja) | 2003-01-07 |
| FR2793809B1 (fr) | 2006-07-28 |
| FR2793809A1 (fr) | 2000-11-24 |
| US7060438B1 (en) | 2006-06-13 |
| CA2374440A1 (fr) | 2000-11-30 |
| WO2000071750A1 (fr) | 2000-11-30 |
| CN1351672A (zh) | 2002-05-29 |
| DE60014887T2 (de) | 2005-10-13 |
| DE60014887D1 (de) | 2004-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2230109T5 (es) | Procedimiento de analisis de la predisposicion genetica de un paciente a por lo menos una enfermedad y amplificacion adaptada a un procedimiento de este tipo. | |
| Conrad et al. | Microsatellite polymorphism in the sexually transmitted human pathogen Trichomonas vaginalis indicates a genetically diverse parasite | |
| JP2009528060A5 (enExample) | ||
| ES2276016T3 (es) | Cebadores y sondas de doble uso para la mejora de ensayos de hibridaciones mediante la interrupcion de la formacion de estructuras secundarias. | |
| JP2002516666A (ja) | 少なくとも一つの特定のヌクレオチド配列の増幅方法及び使用されるプライマー | |
| ES2123775T5 (es) | Procedimiento para la tipificacion de hla-b por medio de iniciadores especificos y conjuntos de sondas. | |
| JP2010528629A (ja) | 遺伝子地図作製及びハプロタイプ決定のための現場（ｉｎｓｉｔｕ）法 | |
| Lauterbach et al. | Molecular typing of HLA-E | |
| ES2260334T3 (es) | Procedimiento de analisis de la predisposicion genetica de un paciente a la diabetes insulino-dependiente, dispositivo y conjunto de cebadores. | |
| TW201300528A (zh) | Ｈｌａ－ｄｑｂ１基因分型的方法及其相關引子 | |
| AU2014336960B2 (en) | Major histocompatibility complex single nucleotide polymorphisms | |
| ES2445709T3 (es) | Método para la identificación por técnicas moleculares de variantes genéticas que no codifican antígeno D (D-) y codifican antígeno C alterado (C+W) | |
| Shankarkumar et al. | HLA A* 02 allele frequencies and B haplotype associations in Western Indians | |
| Gonzalez et al. | Investigation of killer cell immunoglobulin‐like receptor (KIR) gene diversity: KIR2DL2, KIR2DL5 and KIR2DS5 | |
| CA2213731C (en) | Methods and reagents for typing hla class i genes | |
| JP2000511430A (ja) | Ｈｌａ ｄｑｂ１タイピングを決定するためのヌクレオチドプローブおよび方法 | |
| Dunn et al. | A “silent” nucleotide substitution in exon 4 is responsible for the “alternative expression” of HLA-A* 01: 01: 38L through aberrant splicing | |
| ES2884474T3 (es) | Determinación del genotipo subyacente al fenotipo S-s-U- del sistema de grupo sanguíneo MNSs | |
| TW201300543A (zh) | Ｈｌａ－ｃ基因分型的方法及其相關引子 | |
| US11453908B2 (en) | Methods and kits for typing KIR2DL alleles | |
| Lou et al. | The novel HLA‐B* 46: 01: 42 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual. | |
| ES2333518T3 (es) | Metodo y sondas para el diagnostico genetico de la hemocromatosis. | |
| Liu et al. | The novel HLA‐B* 13: 176 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual. | |
| JP6516128B2 (ja) | 抗甲状腺薬誘発性無顆粒球症リスクを判定するための検査方法及び判定用キット | |
| ES2365195T3 (es) | Genotipado hla de alta resolución y alto rendimiento mediante secuenciación clonal. |